Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ponatinib hydrochloride
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients with Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0030, NCI-2011-02941, NCT01424982
Ponatinib Hydrochloride in Treating Patients with Stage IIIB-IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-103, NCI-2013-01802, NCT01813734
Ponatinib Hydrochloride in Treating Patients with Localized or Metastatic Thyroid Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0108, NCI-2013-01589, 130108, 343948, P121010, NCT01838642
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, PAM004-1, PAM005-2, NCT01935336
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Ponatinib Hydrochloride in Treating Patients with Refractory Metastatic Cancers and Genetic Alterations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14078, NCI-2014-01499, 2014C0143, NCT02272998
Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AP24534-14-203, NCI-2015-01086, NCT02467270
Start Over